ACE and pulmonary arterial hypertension: Subjects with PAH-LHD were less commonly treated with phosphodiesterase type 5 inhibitors/guanylate cyclase stimulators and dual oral therapy, while they were more often prescribed with beta-blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, as expected considering their comorbidities.